EGFR and neoplasm: Collectively, these findings demonstrate that the EGFR-driven LUAD exhibits an immunosuppressive tumor microenvironment, characterized by impaired adaptive immune activation and enhanced M2 macrophage polarization, which faithfully reflects the immune landscape observed in both EGFR-mutant LUAD patients and GEMM models.